{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T21:29:04Z","timestamp":1793395744183,"version":"4.5.0"},"reference-count":47,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100015499","name":"Jeonbuk National University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100015499","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100020704","name":"Instituto de Investigaciones Biom\u00e9dicas, Universidad Nacional Aut\u00f3noma de M\u00e9xico","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100020704","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003625","name":"Ministry of Health and Welfare","doi-asserted-by":"publisher","award":["HR22C1832"],"award-info":[{"award-number":["HR22C1832"]}],"id":[{"id":"10.13039\/501100003625","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jidonline.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Investigative Dermatology"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.jid.2025.02.137","type":"journal-article","created":{"date-parts":[[2025,3,3]],"date-time":"2025-03-03T11:48:16Z","timestamp":1741002496000},"page":"2495-2509.e6","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["The Repurposing of Nitazoxanide for Psoriasis Treatment Exerts Therapeutic Effects through Skin Metabolic Reprogramming"],"prefix":"10.1016","volume":"145","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-3065-1145","authenticated-orcid":false,"given":"Jong Yeong","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-8690-4628","authenticated-orcid":false,"given":"Ha Eun","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-9644-3695","authenticated-orcid":false,"given":"Seung Taek","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8830-5479","authenticated-orcid":false,"given":"Jin","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1224-7142","authenticated-orcid":false,"given":"Kyung-Hwa","family":"Nam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-1387-2206","authenticated-orcid":false,"given":"Jun-Young","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-2609-6994","authenticated-orcid":false,"given":"Jin Kyeong","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jid.2025.02.137_bib1","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1007\/s40261-022-01213-y","article-title":"The effect of nitazoxanide on the clinical outcomes in patients with COVID-19: a systematic review and meta-analysis of randomized controlled trials","volume":"42","author":"Abuelazm","year":"2022","journal-title":"Clin Drug Investig"},{"key":"10.1016\/j.jid.2025.02.137_bib2","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.immuni.2020.11.001","article-title":"Ribosome-targeting antibiotics impair T cell effector function and ameliorate autoimmunity by blocking mitochondrial protein synthesis","volume":"54","author":"Almeida","year":"2021","journal-title":"Immunity"},{"key":"10.1016\/j.jid.2025.02.137_bib3","doi-asserted-by":"crossref","first-page":"15731","DOI":"10.1074\/jbc.M117.791863","article-title":"The unintended mitochondrial uncoupling effects of the FDA-approved anti-helminth drug nitazoxanide mitigates experimental parkinsonism in mice","volume":"292","author":"Amireddy","year":"2017","journal-title":"J Biol Chem"},{"key":"10.1016\/j.jid.2025.02.137_bib4","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbc.2021.100864","article-title":"Correction: the unintended mitochondrial uncoupling effects of the FDA-approved anti-helminth drug nitazoxanide mitigates experimental parkinsonism in mice","volume":"297","author":"Amireddy","year":"2021","journal-title":"J Biol Chem"},{"key":"10.1016\/j.jid.2025.02.137_bib5","doi-asserted-by":"crossref","first-page":"82","DOI":"10.2174\/1574886315666200128095958","article-title":"Treatment of psoriasis: a comprehensive review of entire therapies","volume":"15","author":"Bakshi","year":"2020","journal-title":"Curr Drug Saf"},{"key":"10.1016\/j.jid.2025.02.137_bib6","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20202191","article-title":"The metabolism-modulating activity of IL-17 signaling in health and disease","volume":"218","author":"Bechara","year":"2021","journal-title":"J Exp Med"},{"key":"10.1016\/j.jid.2025.02.137_bib7","doi-asserted-by":"crossref","DOI":"10.1016\/j.redox.2019.101255","article-title":"Mitochondria as central hub of the immune system","volume":"26","author":"Breda","year":"2019","journal-title":"Redox Biol"},{"key":"10.1016\/j.jid.2025.02.137_bib8","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0180853","article-title":"Inflammation dependent mTORC1 signaling interferes with the switch from keratinocyte proliferation to differentiation","volume":"12","author":"Buerger","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.jid.2025.02.137_bib9","doi-asserted-by":"crossref","first-page":"2879","DOI":"10.1084\/jem.20061877","article-title":"Orchestration of lymphocyte chemotaxis by mitochondrial dynamics","volume":"203","author":"Campello","year":"2006","journal-title":"J Exp Med"},{"key":"10.1016\/j.jid.2025.02.137_bib10","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1038\/jid.2010.340","article-title":"Integrative responses to IL-17 and TNF-\u03b1 in human keratinocytes account for key inflammatory pathogenic circuits in psoriasis","volume":"131","author":"Chiricozzi","year":"2011","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jid.2025.02.137_bib11","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1016\/j.molmed.2020.04.004","article-title":"Metabolic pathways that control skin homeostasis and inflammation","volume":"26","author":"Cibrian","year":"2020","journal-title":"Trends Mol Med"},{"key":"10.1016\/j.jid.2025.02.137_bib12","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1016\/j.immuni.2009.04.014","article-title":"The mTOR kinase differentially regulates effector and regulatory T cell lineage commitment","volume":"30","author":"Delgoffe","year":"2009","journal-title":"Immunity"},{"key":"10.1016\/j.jid.2025.02.137_bib13","doi-asserted-by":"crossref","first-page":"302","DOI":"10.4049\/jimmunol.2300319","article-title":"IL-17A orchestrates reactive oxygen Species\/HIF1\u03b1-mediated metabolic reprogramming in psoriasis","volume":"212","author":"Dhamija","year":"2024","journal-title":"J Immunol"},{"key":"10.1016\/j.jid.2025.02.137_bib14","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1016\/j.jid.2023.09.275","article-title":"Inhibition of mitochondrial translation ameliorates imiquimod-induced psoriasis-like skin inflammation by targeting V\u03b34+ \u03b3\u03b4 T cells","volume":"144","author":"Dhillon-LaBrooy","year":"2024","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jid.2025.02.137_bib15","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1007\/s13555-023-00910-6","article-title":"Long-term psoriasis control with guselkumab, adalimumab, secukinumab, or ixekizumab in the USA","volume":"13","author":"Fitzgerald","year":"2023","journal-title":"Dermatol Ther (Heidelb)"},{"key":"10.1016\/j.jid.2025.02.137_bib16","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1093\/cid\/ciz100","article-title":"Efficacy and safety of nitazoxanide in addition to standard of care for the treatment of severe acute respiratory illness","volume":"69","author":"Gami\u00f1o-Arroyo","year":"2019","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jid.2025.02.137_bib17","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.jaad.2018.01.003","article-title":"Efficacy and safety of switching to ixekizumab in secukinumab nonresponders with plaque psoriasis: a multicenter retrospective study of interleukin 17A antagonist therapies","volume":"79","author":"Georgakopoulos","year":"2018","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jid.2025.02.137_bib18","doi-asserted-by":"crossref","DOI":"10.1038\/nrdp.2016.82","article-title":"Psoriasis","volume":"2","author":"Greb","year":"2016","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.jid.2025.02.137_bib19","doi-asserted-by":"crossref","first-page":"4726","DOI":"10.1111\/bph.15652","article-title":"Repurposing the anthelmintic praziquantel to treat psoriasis","volume":"178","author":"Hao","year":"2021","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.jid.2025.02.137_bib20","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.4049\/jimmunol.1800013","article-title":"Discovery of the IL-23\/IL-17 signaling pathway and the treatment of psoriasis","volume":"201","author":"Hawkes","year":"2018","journal-title":"J Immunol"},{"key":"10.1016\/j.jid.2025.02.137_bib21","doi-asserted-by":"crossref","DOI":"10.3389\/av.2023.11612","article-title":"The modulation of metabolomics and antioxidant stress is involved in the effect of nitazoxanide against influenza A virus in vitro","volume":"67","author":"Huang","year":"2023","journal-title":"Acta Virol"},{"key":"10.1016\/j.jid.2025.02.137_bib22","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1126\/science.aal3535","article-title":"Anti-inflammatory effect of IL-10 mediated by metabolic reprogramming of macrophages","volume":"356","author":"Hoshi","year":"2017","journal-title":"Science"},{"key":"10.1016\/j.jid.2025.02.137_bib23","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.exppara.2016.10.012","article-title":"Nitazoxanide induces in vitro metabolic acidosis in Taenia crassiceps cysticerci","volume":"171","author":"Isac","year":"2016","journal-title":"Exp Parasitol"},{"key":"10.1016\/j.jid.2025.02.137_bib24","doi-asserted-by":"crossref","DOI":"10.1016\/j.exppara.2019.107792","article-title":"In vitro nitazoxanide exposure affects energetic metabolism of Taenia crassiceps","volume":"208","author":"Isac","year":"2020","journal-title":"Exp Parasitol"},{"key":"10.1016\/j.jid.2025.02.137_bib25","article-title":"Imidazole propionate ameliorates atopic dermatitis-like skin lesions by inhibiting mitochondrial ROS and mTORC2","volume":"15","author":"Kim","year":"2024","journal-title":"Front Immunol"},{"key":"10.1016\/j.jid.2025.02.137_bib26","doi-asserted-by":"crossref","first-page":"4216","DOI":"10.1016\/j.cell.2022.09.031","article-title":"En masse organoid phenotyping informs metabolic-associated genetic susceptibility to NASH","volume":"185","author":"Kimura","year":"2022","journal-title":"Cell"},{"key":"10.1016\/j.jid.2025.02.137_bib27","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1016\/S0140-6736(03)12954-6","article-title":"Psoriasis","volume":"361","author":"Lebwohl","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.jid.2025.02.137_bib28","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2024.116195","article-title":"Nitazoxanide reduces inflammation and bone erosion in mice with collagen-induced arthritis via inhibiting the JAK2\/STAT3 and NF-\u03baB pathways in fibroblast-like synoviocytes","volume":"171","author":"Li","year":"2024","journal-title":"Biomed Pharmacother"},{"key":"10.1016\/j.jid.2025.02.137_bib29","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.apsb.2019.07.006","article-title":"Discovery of nitazoxanide-based derivatives as autophagy activators for the treatment of Alzheimer\u2019s disease","volume":"10","author":"Li","year":"2020","journal-title":"Acta Pharm Sin B"},{"key":"10.1016\/j.jid.2025.02.137_bib30","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1111\/bph.15949","article-title":"Repurposing nitazoxanide as a novel anti-atherosclerotic drug based on mitochondrial uncoupling mechanisms","volume":"180","author":"Ma","year":"2023","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.jid.2025.02.137_bib31","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.cmet.2014.05.004","article-title":"The glucose transporter Glut1 is selectively essential for CD4 T cell activation and effector function","volume":"20","author":"Macintyre","year":"2014","journal-title":"Cell Metab"},{"key":"10.1016\/j.jid.2025.02.137_bib32","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1038\/s41577-022-00746-9","article-title":"IL-17 and IL-17-producing cells in protection versus pathology","volume":"23","author":"Mills","year":"2023","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.jid.2025.02.137_bib33","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1038\/nri3701","article-title":"Integrating canonical and metabolic signalling programmes in the regulation of T cell responses","volume":"14","author":"Pollizzi","year":"2014","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.jid.2025.02.137_bib34","doi-asserted-by":"crossref","first-page":"2168","DOI":"10.1016\/j.jid.2018.04.019","article-title":"Ixekizumab pharmacokinetics, anti-drug antibodies, and efficacy through 60 weeks of treatment of moderate to severe plaque psoriasis","volume":"138","author":"Reich","year":"2018","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jid.2025.02.137_bib35","doi-asserted-by":"crossref","DOI":"10.3389\/fmolb.2023.1201912","article-title":"Psoriasis immunometabolism: progress on metabolic biomarkers and targeted therapy","volume":"10","author":"Sarandi","year":"2023","journal-title":"Front Mol Biosci"},{"key":"10.1016\/j.jid.2025.02.137_bib36","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1016\/j.celrep.2018.11.018","article-title":"Drp1 controls effective T cell immune-surveillance by regulating T cell migration, proliferation, and cMyc-dependent metabolic reprogramming","volume":"25","author":"Simula","year":"2018","journal-title":"Cell Rep"},{"key":"10.1016\/j.jid.2025.02.137_bib37","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1038\/s41419-020-2649-z","article-title":"Mitochondria in skin health, aging, and disease","volume":"11","author":"Sreedhar","year":"2020","journal-title":"Cell Death Dis"},{"key":"10.1016\/j.jid.2025.02.137_bib38","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2024.103530","article-title":"Formation and clinical effects of anti-drug antibodies against biologics in psoriasis treatment: an analysis of current evidence","volume":"23","author":"Sun","year":"2024","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.jid.2025.02.137_bib39","doi-asserted-by":"crossref","first-page":"5270","DOI":"10.1002\/jcp.29413","article-title":"Repurposing an old drug for new use: niclosamide in psoriasis-like skin inflammation","volume":"235","author":"Thatikonda","year":"2020","journal-title":"J Cell Physiol"},{"key":"10.1016\/j.jid.2025.02.137_bib40","doi-asserted-by":"crossref","first-page":"462","DOI":"10.4049\/jimmunol.1102224","article-title":"IL-22 is required for imiquimod-induced psoriasiform skin inflammation in mice","volume":"188","author":"Van Belle","year":"2012","journal-title":"J Immunol"},{"key":"10.1016\/j.jid.2025.02.137_bib41","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1016\/j.bbadis.2018.02.003","article-title":"PI3K\/AKT\/mTOR activation and autophagy inhibition plays a key role in increased cholesterol during IL-17A mediated inflammatory response in psoriasis","volume":"1864","author":"Varshney","year":"2018","journal-title":"Biochim Biophys Acta Mol Basis Dis"},{"key":"10.1016\/j.jid.2025.02.137_bib42","doi-asserted-by":"crossref","first-page":"2285","DOI":"10.3389\/fimmu.2019.02285","article-title":"Targeting T cell metabolism in inflammatory skin disease","volume":"10","author":"von Meyenn","year":"2019","journal-title":"Front Immunol"},{"key":"10.1016\/j.jid.2025.02.137_bib43","doi-asserted-by":"crossref","first-page":"e01956","DOI":"10.1128\/AAC.01956-19","article-title":"Early bactericidal activity trial of nitazoxanide for pulmonary tuberculosis","volume":"64","author":"Walsh","year":"2020","journal-title":"antimicrob agents chemother"},{"key":"10.1016\/j.jid.2025.02.137_bib44","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1189\/jlb.1112562","article-title":"Regulatory B cells suppress imiquimod-induced, psoriasis-like skin inflammation","volume":"94","author":"Yanaba","year":"2013","journal-title":"J Leukoc Biol"},{"key":"10.1016\/j.jid.2025.02.137_bib45","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1001\/jamadermatol.2020.4202","article-title":"Randomized trial replication using observational data for comparative effectiveness of secukinumab and ustekinumab in psoriasis: a study from the British Association of Dermatologists biologics and immunomodulators register","volume":"157","author":"Yiu","year":"2021","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jid.2025.02.137_bib46","doi-asserted-by":"crossref","DOI":"10.1080\/09546634.2024.2349658","article-title":"Comparative analysis of persistence and remission with guselkumab versus secukinumab and ixekizumab in the United States","volume":"35","author":"Zhdanava","year":"2024","journal-title":"J Dermatolog Treat"},{"key":"10.1016\/j.jid.2025.02.137_bib47","doi-asserted-by":"crossref","DOI":"10.1016\/j.cbi.2024.111013","article-title":"Nitazoxanide protects against experimental ulcerative colitis through improving intestinal barrier and inhibiting inflammation","volume":"395","author":"Zhu","year":"2024","journal-title":"Chem Biol Interact"}],"container-title":["Journal of Investigative Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022202X25002982?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022202X25002982?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T01:23:15Z","timestamp":1790817795000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022202X25002982"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":47,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["S0022202X25002982"],"URL":"https:\/\/doi.org\/10.1016\/j.jid.2025.02.137","relation":{},"ISSN":["0022-202X"],"issn-type":[{"value":"0022-202X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Repurposing of Nitazoxanide for Psoriasis Treatment Exerts Therapeutic Effects through Skin Metabolic Reprogramming","name":"articletitle","label":"Article Title"},{"value":"Journal of Investigative Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jid.2025.02.137","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Society for Investigative Dermatology. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}